Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05722392Recruiting
Two-step surgery for localized prostate cancer
This trial studies a “two-step” type of prostate removal surgery for men with localized prostate cancer, focusing on whether it is safe and effective. It may help if you have certain prostate size, PSA level, and tumor features that match their criteria.
Guangzhou, GuangdongAges Any age - NCT02638389RecruitingPhase 3
Sirolimus for hard-to-treat vascular birthmarks
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
Brussels, Brussels CapitalAges 3 months–70 years - NCT04959903RecruitingPhase 1/Phase 2
SMART101 after T-cell–depleted bone marrow transplant for blood cancers
This early-phase study tests SMART101 given after a T-cell–depleted (T-cell removed) donor bone marrow transplant. It aims to see if the treatment is safe and can help control certain high-risk blood cancers in children and adults.
New York, New YorkAges Any age - NCT05757245RecruitingPhase 1
Safety and effectiveness of GMCN-508A for transfusion-dependent alpha thalassemia
This Phase 1 study tests a new medicine (GMCN-508A) to see how safe it is and whether it can help people with transfusion-dependent alpha thalassemia. Participants are also expected to follow a treatment plan that includes stem cell transplantation preparation.
Nanning, GuangxiAges 5–35 - NCT05814952Recruiting
LX103 eye treatment for X-linked retinoschisis
This trial studies whether LX103 can improve vision and is safe for people with X-linked retinoschisis (XLRS) caused by RS1 gene changes. It focuses on a specific level of vision in the study eye and checks for medical conditions that could affect eye testing or safety.
ShanghaiAges 6 years+ - NCT05762510RecruitingEarly Phase 1
Testing a gene-based treatment for transfusion-dependent thalassemia
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
Nanning, GuangxiAges 5–35 - NCT05854823Recruiting
Reduced radiation after surgery for advanced head and neck cancer
This trial looks at whether giving less (de-escalated) radiation after surgery is as effective and safer for people with locally advanced head and neck squamous cell carcinoma who had a strong response to treatment before surgery. If you had no remaining cancer or only very small amounts of cancer left in the surgical specimen, this approach may help reduce side effects while keeping control of the disease.
Zhuhai, GuangdongAges 18–70 - NCT05561088Recruiting
Head acupuncture after stroke clot removal
This trial studies whether doing head acupuncture after a procedure to remove a stroke-causing blood clot can improve recovery and safety. You may be considered if you had endovascular clot removal within 24 hours and meet specific brain-scan and stroke-severity measures.
Xi'an, ShaanxiAges 18–100 - NCT05856383Recruiting
HER2-positive metastatic breast cancer drug combination study
This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.
Hangzhou, ZhejiangAges 18 years+ - NCT04602962Recruiting
Fertility treatments and fertility preservation study
This study looks at how safe and effective fertility treatments are and how well fertility preservation options work. It is meant for people who are struggling to get pregnant or who need to protect their future fertility.
StockholmAges Up to 56 years - NCT05916898Recruiting
Shockwave treatment after difficult stent expansion
This registry studies how well shockwave therapy works when a previously placed heart stent does not expand well, especially when the artery is quite calcified. Your care team would use it after other tools to prepare the blockage have not worked.
Legnica, Lower Silesian VoivodeshipAges 18–99 - NCT05939661RecruitingPhase 2
Total treatment before surgery for early rectal cancer
This Phase 2 study tests a “total neoadjuvant” approach, meaning you receive cancer treatment before surgery, to improve safety and effectiveness for rectal cancer. It may help by shrinking the tumor and planning a more effective operation, while researchers carefully track side effects.
OsakaAges 18 years+ - NCT05701293Recruiting
RenZan stent check for leg artery narrowing
This trial follows how well the RenZan stent works and how safe it is for people with blocked or badly narrowed thigh-to-knee leg arteries. It may help by improving blood flow and adding careful monitoring to see how outcomes compare over time.
SienaAges 18 years+ - NCT05962840RecruitingPhase 4
Rituximab plus telitacicept for ANCA vasculitis
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
BeijingAges 18–65 - NCT05965284RecruitingPhase 4
Telitacicept to help keep ANCA vasculitis in remission
This trial studies telitacicept to see if it can help keep ANCA-associated vasculitis in remission after initial treatment with steroids and rituximab. It may help prevent future flare-ups, while closely watching for side effects.
Beijing, Beijing MunicipalityAges 18–65 - NCT05534672RecruitingPhase 3
Rapamycin for drug-resistant seizures in tuberous sclerosis
This trial tests whether rapamycin (compared with a placebo) can reduce seizures caused by tuberous sclerosis complex (TSC) that have not been controlled by usual medicines. If you qualify, you may be helping doctors find a safer and more effective option for seizure control.
LodzAges 3 months–50 years - NCT05983783RecruitingPhase 3
Testing two drug combinations for advanced prostate cancer
This trial compares two combinations of drugs for men with metastatic hormone-sensitive prostate cancer that has a high tumor burden. One group gets rezvilutamide plus hormone therapy and chemotherapy, while the other gets rezvilutamide plus hormone therapy alone. The goal is to see which is more effective and safe.
Nanjing, JiangsuAges 40–80 - NCT06012552RecruitingPhase 2
Tianeptine for COVID-19 brain fog
This study tests whether the medication tianeptine can improve brain fog and thinking problems that persist after COVID-19. It may help if you are 18 or older, have had COVID-19, and have noticed new memory or concentration issues.
WarsawAges 18 years+ - NCT05947669RecruitingPhase 3
Infliximab for diarrhea or colitis from immune cancer therapy
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
AalborgAges 18 years+ - NCT05774288Recruiting
Testing a device to close a heart opening called PFO
This trial studies whether a Cera™ device is safe and effective for closing a patent foramen ovale (PFO), a small hole in the heart. It is for adults whose PFO is linked to certain types of stroke or ongoing clot-related events.
Beijing, Beijing MunicipalityAges 18–60 - NCT05338190RecruitingPhase 3
Belimumab added to rituximab for chronic immune thrombocytopenia
This Phase 3 study tests whether adding an injection called belimumab (or a placebo) to rituximab works better and is safe for adults with long-lasting immune thrombocytopenia (ITP). You may be eligible if your platelet counts stay low despite prior steroid and/or IVIG treatment and if infections, vaccines, and other health conditions meet the study rules.
CréteilAges 18 years+ - NCT06045091RecruitingEarly Phase 1
BCMA-targeted CAR-NK cells for multiple myeloma or plasma cell leukemia
This trial tests an experimental therapy using immune cells (CAR-NK cells) designed to target and kill cancer cells in people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to treatment. The goal is to see if it is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06056115Recruiting
Tislelizumab for lung cancer with brain metastases
This trial tests a drug called tislelizumab for people with advanced lung adenocarcinoma that has spread to the brain but is not causing symptoms. It is for those who have not had prior treatment and whose tumors do not have certain gene changes.
Shijiazhuang, HebeiAges 18–75 - NCT04443010RecruitingPhase 1/Phase 2
Testing a new protein drug with standard treatment for new glioblastoma
This Phase 1/2 study tests whether adding a drug called L19TNF to standard chemoradiotherapy is safe and may work better than standard treatment alone for newly diagnosed glioblastoma. If you qualify, you would be closely monitored for side effects and treatment response.
ZurichAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.